Genetically Modified HSPCs Reprogram Immune Microenvironment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapeutic strategies for targeting and eliminating distant metastatic lesions are limited by immunosuppression in the tumor and pre-metastatic tumor microenvironment, necessitating an effective method to harness the immune system for metastasis prevention and treatment.
Innovation Solution
Genetically modified hematopoietic stem and progenitor cells, mesenchymal cells, or both, containing a lentiviral vector with a transgene, are used to produce genetically engineered myeloid cells that can be administered to reprogram the immune microenvironment, reversing immune suppression and enhancing anti-tumor immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunotherapeutic strategies (e.g., CAR-T cell therapy) are used to target metastatic lesions, then anti-tumor immunity is activated, but the therapy is limited by immunosuppression in the tumor and pre-metastatic tumor microenvironment
Solution Approach 1:
The patent introduces genetically modified myeloid cells as intermediary mediators that traverse the immunosuppressive tumor microenvironment. These cells carry transgenes encoding immunomodulatory proteins (such as cytokines or chemokines) that actively counteract immunosuppressive factors, thereby enabling effective anti-tumor immunity despite the presence of harmful immunosuppressive factors in the tumor niche.
Solution Approach 2:
The patent converts the harmful immunosuppressive environment into a beneficial setting by using myeloid cells that can sense and respond to suppressive cues. These cells differentiate into functionally active immunomodulatory phenotypes within the tumor microenvironment, transforming the previously hostile immunosuppressive niche into a supportive environment for anti-tumor immune responses.
2Reliability
If genetically modified hematopoietic stem and progenitor cells and mesenchymal cells are used to reprogram the immune microenvironment, then immune suppression is reversed and anti-tumor immunity is enhanced, but the device complexity increases due to cellular engineering requirements
Solution Approach 1:
The patent segments the complex task of immune reprogramming into distinct functional modules: (1) generating genetically modified hematopoietic stem and progenitor cells with specific transgenes, (2) generating genetically modified mesenchymal cells with specific transgenes, and (3) administering these cells to reprogram the immune microenvironment. This modular approach allows independent optimization of each cell type's function while simplifying the overall therapeutic strategy.
Solution Approach 2:
The patent employs a universal platform using lentiviral vectors to deliver transgenes across multiple cell types (hematopoietic stem and progenitor cells and mesenchymal cells). This multi-functional vector system enables the same delivery mechanism to create different functional cell populations tailored for specific therapeutic roles, thereby reducing the complexity of developing separate delivery systems for each cell type.
3Reliability
If prophylactic and/or treatment methods for metastasis are developed, then metastasis prevention is achieved, but the understanding of key regulators of the metastasis process is still insufficient
Solution Approach 1:
The patent incorporates feedback mechanisms through the use of myeloid cells that can sense and respond to the tumor microenvironment's immunosuppressive signals. These cells continuously monitor and adapt their immunomodulatory function based on the local biological conditions, providing real-time feedback that enhances metastasis prevention while simultaneously generating data about the regulatory mechanisms at play in the tumor niche.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively increases survival time, reduces tumor growth, prevents metastasis, and activates immune responses, demonstrating significant therapeutic impact in preclinical models by promoting cytotoxic T cell responses and reversing the core immune suppression program in the metastatic niche.
Implementation Method 1
transfecting the HSPCs with a vector (e.g., lentiviral vector) comprising a transgene
Implementation Method 2
the cells contain a vector (e.g., lentiviral vector) comprising a transgene
Implementation Method 3
reprogram the immune microenvironment, reversing immune suppression and enhancing anti-tumor immunity
Implementation Method 4
activates immune responses, demonstrating significant therapeutic impact in preclinical models by promoting cytotoxic T cell responses
Implementation Method 5
reduces tumor growth, prevents metastasis
Implementation Method 6
increases survival time
Data Source
AI summary
Provided are compositions comprising genetically modified hematopoietic stem and progenitor cells (HSPCs) and/or genetically modified mesenchymal cells, wherein the cells contain a vector comprising a transgene, as well as methods of producing the genetically modified HSPCs and genetically modified mesenchymal cells, and methods of treating or preventing cancer (e.g., metastasis) and neurodegenerative conditions, autoimmune disorders, and inflammatory disorders.